Stifel raised the firm’s price target on TransMedics (TMDX) to $130 from $115 and keeps a Hold rating on the shares. The firm updated models across its medical technology and supplies coverage following Q4 reporting from the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics Group Signals Strong Growth in Earnings Call
- TransMedics price target raised to $168 from $154 at Baird
- TransMedics price target raised to $170 from $155 at Evercore ISI
- TransMedics price target raised to $175 from $150 at Oppenheimer
- TransMedics price target raised to $149 from $114 at JPMorgan